ContraVir Pharmaceuticals (NASDAQ: CTRV) is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. One compound, TXL™ is a highly potent analog of the successful antiviral drug Viread® and is currently in phase 2a of development. The company’s other anti-HBV compound, CRV431, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine, an orally available nucleoside analogue prodrug that is currently in phase 3 for the treatment of herpes zoster. For more information, visit the company’s website at www.contravir.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com